Q3 EPS Estimates for AngioDynamics Lowered by Zacks Research

AngioDynamics, Inc. (NASDAQ:ANGO) – Equities researchers at Zacks Research cut their Q3 2026 earnings per share (EPS) estimates for AngioDynamics in a report issued on Tuesday, March 25th. Zacks Research analyst D. Dey now forecasts that the medical instruments supplier will post earnings of ($0.05) per share for the quarter, down from their prior forecast of ($0.04). The consensus estimate for AngioDynamics’ current full-year earnings is ($0.37) per share. Zacks Research also issued estimates for AngioDynamics’ Q4 2026 earnings at $0.00 EPS, FY2026 earnings at ($0.28) EPS and FY2027 earnings at ($0.18) EPS.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business had revenue of $72.90 million during the quarter, compared to analysts’ expectations of $70.93 million. During the same period in the prior year, the business earned ($0.05) earnings per share. The company’s quarterly revenue was down .1% compared to the same quarter last year.

Separately, HC Wainwright raised their price objective on shares of AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, January 10th.

AngioDynamics Stock Down 3.4 %

Shares of NASDAQ:ANGO opened at $9.50 on Friday. AngioDynamics has a 52-week low of $5.47 and a 52-week high of $13.50. The stock has a market cap of $384.43 million, a P/E ratio of -1.69 and a beta of 0.56. The business has a fifty day moving average of $10.41 and a two-hundred day moving average of $8.80.

Institutional Trading of AngioDynamics

Hedge funds have recently made changes to their positions in the business. Divisadero Street Capital Management LP acquired a new stake in AngioDynamics during the 4th quarter worth approximately $4,714,000. Segall Bryant & Hamill LLC raised its stake in shares of AngioDynamics by 55.3% in the fourth quarter. Segall Bryant & Hamill LLC now owns 1,415,156 shares of the medical instruments supplier’s stock valued at $12,963,000 after acquiring an additional 503,713 shares in the last quarter. Marshall Wace LLP boosted its holdings in AngioDynamics by 1,335.1% in the fourth quarter. Marshall Wace LLP now owns 476,824 shares of the medical instruments supplier’s stock valued at $4,368,000 after purchasing an additional 443,598 shares during the period. Paradigm Capital Management Inc. NY acquired a new position in AngioDynamics during the 4th quarter worth $3,701,000. Finally, Nuveen Asset Management LLC increased its holdings in AngioDynamics by 37.4% during the 4th quarter. Nuveen Asset Management LLC now owns 1,296,366 shares of the medical instruments supplier’s stock worth $11,875,000 after purchasing an additional 353,070 shares during the period. Institutional investors and hedge funds own 89.43% of the company’s stock.

Insider Buying and Selling

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the business’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total value of $49,978.60. Following the sale, the senior vice president now owns 41,817 shares in the company, valued at approximately $514,767.27. The trade was a 8.85 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.40% of the stock is currently owned by corporate insiders.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.